S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
"Prepare for Five Years of Famine" (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
"Prepare for Five Years of Famine" (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
"Prepare for Five Years of Famine" (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
"Prepare for Five Years of Famine" (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
OTCMKTS:RCDTF

Recordati Industria Chimica e Farmaceutica - RCDTF Stock Forecast, Price & News

$44.48
0.00 (0.00%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$44.48
$44.48
50-Day Range
$41.23
$44.48
52-Week Range
$41.23
$44.48
Volume
N/A
Average Volume
50 shs
Market Capitalization
$9.18 billion
P/E Ratio
20.13
Dividend Yield
N/A
Price Target
$43.00
RCDTF stock logo

About Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Stock

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Receive RCDTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter.

RCDTF Stock News Headlines

Recordati manca previsioni degli analisti
Recordati reports FY results
See More Headlines
Receive RCDTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter.

RCDTF Company Calendar

Today
8/16/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:RCDTF
Previous Symbol
NASDAQ:RCDTF
CIK
N/A
Employees
4,303
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.00
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
-3.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$456.64 million
Pretax Margin
29.33%

Debt

Sales & Book Value

Annual Sales
$1.87 billion
Cash Flow
$3.00 per share
Book Value
$7.92 per share

Miscellaneous

Free Float
N/A
Market Cap
$9.18 billion
Optionable
Not Optionable
Beta
0.26

Key Executives

  • Dr. Robert Koremans M.D. (Age 60)
    CEO & Director
    Comp: $135.34k
  • Ms. Cathrin Petty (Age 49)
    Exec. Director
  • Mr. Giampiero Mazza (Age 53)
    Exec. Director
  • Mr. Giorgio De Palma (Age 48)
    Exec. Director
  • Mr. Luigi Felice La Corte (Age 53)
    Group CFO & Exec. Director
  • Ms. Federica De Medici
    Director of Investor Relations & Corp. Communications
  • Ms. Daria Ghidoni
    Group Gen. Counsel
  • Mr. Giovanni Minora
    Group Audit & Compliance
  • Mr. Gabriele Finzi
    Exec. VP of Corp. Devel. & Licensing
  • Mr. Giuseppe Gualazzini (Age 63)
    Sr. VP of Group HR













RCDTF Stock - Frequently Asked Questions

Should I buy or sell Recordati Industria Chimica e Farmaceutica stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Recordati Industria Chimica e Farmaceutica in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RCDTF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RCDTF, but not buy additional shares or sell existing shares.
View RCDTF analyst ratings
or view top-rated stocks.

What is Recordati Industria Chimica e Farmaceutica's stock price forecast for 2022?

4 brokerages have issued 1-year price objectives for Recordati Industria Chimica e Farmaceutica's shares. Their RCDTF share price forecasts range from $42.00 to $44.00. On average, they predict the company's share price to reach $43.00 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.
View analysts price targets for RCDTF
or view top-rated stocks among Wall Street analysts.

How have RCDTF shares performed in 2022?

Recordati Industria Chimica e Farmaceutica's stock was trading at $63.9637 at the beginning of the year. Since then, RCDTF shares have decreased by 30.5% and is now trading at $44.4807.
View the best growth stocks for 2022 here
.

Are investors shorting Recordati Industria Chimica e Farmaceutica?

Recordati Industria Chimica e Farmaceutica saw a increase in short interest in July. As of July 15th, there was short interest totaling 432,200 shares, an increase of 33.4% from the June 30th total of 324,000 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 4,322.0 days.
View Recordati Industria Chimica e Farmaceutica's Short Interest
.

What is Recordati Industria Chimica e Farmaceutica's stock symbol?

Recordati Industria Chimica e Farmaceutica trades on the OTCMKTS under the ticker symbol "RCDTF."

How do I buy shares of Recordati Industria Chimica e Farmaceutica?

Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Recordati Industria Chimica e Farmaceutica's stock price today?

One share of RCDTF stock can currently be purchased for approximately $44.48.

How much money does Recordati Industria Chimica e Farmaceutica make?

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) has a market capitalization of $9.18 billion and generates $1.87 billion in revenue each year. The company earns $456.64 million in net income (profit) each year or $2.21 on an earnings per share basis.

How many employees does Recordati Industria Chimica e Farmaceutica have?

The company employs 4,303 workers across the globe.

How can I contact Recordati Industria Chimica e Farmaceutica?

Recordati Industria Chimica e Farmaceutica's mailing address is Via Matteo Civitali 1, Milano L6, 20148. The official website for the company is www.recordati.com. The company can be reached via phone at 390-248-7871, via email at investorelations@recordati.it, or via fax at 39-02-4007-3747.

This page (OTCMKTS:RCDTF) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.